[PDF][PDF] TVS 联合实时剪切波弹性成像对剖宫产术后SP 再次分娩方式的预测
赵妍妍， 南瑞霞， 万映， 冼少荣 - 河北医学 - hbyxzzs.cn
… Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer:
a multicentreꎬ … Effect of anlotinib as a thirdLine or further treatment on overall survival of …
a multicentreꎬ … Effect of anlotinib as a thirdLine or further treatment on overall survival of …
[PDF][PDF] 安罗替尼三线治疗晚期肺癌的临床疗效及安全性分析
孙新苑， 何超然， 娄安琦， 俞静， 余俊先 - 临床药物治疗杂志, 2020 - lcywzlzz.com
… of anlotinib in the third-line treatment of advanced lung cancer… trial of anlotinib in patients
with advanced non-small cell lung … of third-line treatment with anlotinib in patients with refractory …
with advanced non-small cell lung … of third-line treatment with anlotinib in patients with refractory …
[HTML][HTML] 安罗替尼治疗KRAS 突变型晚期肺腺癌1 例
苏雨栋， 孟昭婷， 徐晓燕， 王心悦， 左冉… - … Journal of Lung …, 2018 - ncbi.nlm.nih.gov
… of advanced non-small cell lung cancer (NSCLC) patients has … treatment plans at home and
abroad for third-line and above … anlotinib therapy revealed multiple metastases in bilateral …
abroad for third-line and above … anlotinib therapy revealed multiple metastases in bilateral …
[HTML][HTML] 安罗替尼治疗晚期非小细胞肺癌的Meta 临床评价
范亚莉， 魏娜， 张惠民， 范阳阳， 山维， 米婷… - Advances in Clinical …, 2023 - hanspub.org
… of anlotinib in the treatment of advanced non-small cell lung cancer. Methods: Taking “… drug
for the third-line treatment of advanced non-small cell lung cancer, anlotinib can significantly …
for the third-line treatment of advanced non-small cell lung cancer, anlotinib can significantly …
[HTML][HTML] 不同机制所致的血管紊乱化生长的共同干预——安罗替尼治疗右肺鳞癌合并血栓闭塞性脉管炎1 例
郝慧娟， 张旻， 张国清， 朱慧， 包婺平 - Chinese Journal of Lung …, 2020 - ncbi.nlm.nih.gov
… Anlotinib, as a third-line therapy, is recommended for patients with refractory advanced
non-small cell lung … We presented a case report of a patient suffering from right lung squamous …
non-small cell lung … We presented a case report of a patient suffering from right lung squamous …
盐酸安罗替尼治疗晚期非小细胞肺癌的近期疗效及相关预测指标
王伟， 谢宵靓， 燕迪迪 - 肿瘤防治研究, 2020 - zlfzyj.com
… Conclusion For patients with non-small cell lung cancer progressing after the second-line
treatment, the third-line treatment with anlotinib is safe and effective. Patients with ECOG score…
treatment, the third-line treatment with anlotinib is safe and effective. Patients with ECOG score…
肺癌靶向治疗药物的心血管毒性
安涛， 韩森 - 中国肿瘤临床, 2021 - cjco.cn
: 肺癌靶向治疗相关的心血管毒性并不少见. 心律失常可能是肺癌靶向治疗中最突出的心血管毒性
, 其中以QT 间期延长的危害最大. 在接受奥希替尼和间变性淋巴瘤激酶(anaplastic lymphoma …
, 其中以QT 间期延长的危害最大. 在接受奥希替尼和间变性淋巴瘤激酶(anaplastic lymphoma …
[PDF][PDF] 盐酸安罗替尼治疗晚期非小细胞肺癌的临床观察
金振兴， 杜秀平 - 临床与病理杂志, 2020 - cdn.amegroups.cn
… anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: The
clinical data of 45 patients with advanced non-small cell lung … as third-line treatment in EGFR …
clinical data of 45 patients with advanced non-small cell lung … as third-line treatment in EGFR …
[PDF][PDF] 信迪利单抗致免疫相关神经系统不良反应的药学监护
张关敏， 宋楠， 高敏， 高雨农， 张艳华 - 医药导报, 2020 - yydbzz.com
… line therapy in patients with refractory advanced non-small-cell … Management of
anlotinibrelated adverse events in patients with advanced non-small cell lung cancer:experiences in …
anlotinibrelated adverse events in patients with advanced non-small cell lung cancer:experiences in …
[HTML][HTML] 安罗替尼在非小细胞肺癌的治疗进展及不良反应管理
卢鑫， 姜军 - Advances in Clinical Medicine, 2022 - hanspub.org
… of non-small cell lung can-cer. Anlotinib is a novel small molecule multitarget tyrosine kinase
… This article reviews the progress of antirotinib in the treatment of non-small cell lung cancer …
… This article reviews the progress of antirotinib in the treatment of non-small cell lung cancer …